A molecular graded prognostic assessment (molGPA) model specific for estimating survival in lung cancer patients with leptomeningeal metastases
Leptomeningeal metastases (LM) are a severe complication of systemic cancer usually occurring in advanced stages which affect approximately 1 –10% of patients with solid tumors. [1–6] The incidence of LM (3–5%) in advanced NSCLC has increased over the last 10 years, especially in subgroups of patients with targetable mutations [6–8]. Although therapies such as molecular targeted treatments and immunotherapies have been described, standard treatment for LM is yet to be established [6,8–13].The median OS of lung cancer patients with LM is poor though with improvement from a historical 1–3 months to 3–11 months by modern systemic therapies [6,7,9].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Kai Yin, Yang-Si Li, Mei-Mei Zheng, Ben-Yuan Jiang, Wen-Feng Li, Jin-Ji Yang, Hai-Yan Tu, Qing Zhou, Wen-Zhao Zhong, Xue-Ning Yang, Hua-Jun Chen, Hong-Hong Yan, Lin-Lin Li, Yi-Long Wu, Xu-Chao Zhang Source Type: research
More News: Cancer | Cancer & Oncology | History of Medicine | Immunotherapy | Lung Cancer | Neoplastic Meningitis | Non-Small Cell Lung Cancer